Valuation: Altimmune, Inc.

Market Cap 539M 473M 440M 404M 759M 51.88B 770M 5.22B 2.04B 25.5B 2.02B 1.98B 88.18B P/E 2026 *
-4.12x
P/E 2027 * -3.65x
Enterprise Value 94.19M 82.73M 76.94M 70.6M 133M 9.07B 135M 914M 357M 4.46B 354M 346M 15.42B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.59%
Yield 2026 *
-
Yield 2027 * -
1 day-2.46%
1 week-3.48%
Current month-8.88%
1 month-3.48%
3 months-2.81%
6 months-49.64%
Current year-23.27%
1 week 2.75
Extreme 2.75
2.91
1 month 2.75
Extreme 2.75
3.4
Current year 2.56
Extreme 2.56
6.44
1 year 2.56
Extreme 2.56
6.44
3 years 2.09
Extreme 2.09
14.84
5 years 2.09
Extreme 2.09
23.49
10 years 1.51
Extreme 1.51
237.3
Manager TitleAgeSince
Chief Executive Officer 58 01/01/2026
Director of Finance/CFO 70 11/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 58 01/09/2003
Chairman 78 01/01/2018
Director/Board Member 76 01/07/2012
Date Insider Type Main position Quantity % Market Cap.
5/1/26 A Free

Director

48,800 0.0251%
5/1/26 A Free

Director

48,800 0.0251%
5/1/26 A Free

Director

48,800 0.0251%
Change 5-day change 1-year change 3-year change Capi.($)
-2.46%-3.48%-32.11%-7.67% 539M
+0.93%+6.97%+59.60%+68.35% 57.28B
-1.92%+6.03%+40.64%+83.42% 54.99B
-0.46%-1.29%+2.86%+428.78% 23.18B
-2.97%-2.35%-22.53%-16.40% 22.59B
-0.36%+5.73%+24.13%-6.24% 20.46B
-1.34%+0.51%+26.03%-29.41% 17.56B
-1.44%+5.67%+38.77%+504.71% 15.67B
-1.30%-5.02%+170.77%+291.37% 14.46B
-0.50%-0.98%+21.43%+180.07% 13.92B
Average -1.18%+0.80%+32.96%+149.70% 24.06B
Weighted average by Cap. -0.88%+2.08%+39.54%+133.18%

Financials

2026 *2027 *
Net sales - -
Net income -108M -94.45M -87.84M -80.6M -151M -10.36B -154M -1.04B -408M -5.09B -404M -395M -17.6B -131M -115M -107M -98.53M -185M -12.66B -188M -1.28B -498M -6.22B -493M -483M -21.52B
Net Debt -444M -390M -363M -333M -626M -42.81B -636M -4.31B -1.68B -21.04B -1.67B -1.63B -72.76B -340M -298M -278M -255M -479M -32.72B -486M -3.3B -1.29B -16.09B -1.28B -1.25B -55.62B
Logo Altimmune, Inc.
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Employees
57
Date Price Change Volume
24/07/26 $2.770 -2.46% 1,911,556
23/07/26 $2.840 +1.07% 1,625,861
22/07/26 $2.810 -0.35% 2,290,537
21/07/26 $2.820 +0.36% 1,984,647
20/07/26 $2.810 -2.09% 2,614,486
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2.770USD
Average target price
16.89USD
Spread / Average Target
+509.71%

Quarterly revenue - Rate of surprise